Senseonics Holdings opened lower at $10.35, compared with its previous close of $10.42. In the last trading session, the stock traded between $10.01 and $10.70. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Senseonics Holdings is now worth
$ 13.56
Resulting in a loss of
$ 86.44 (86.44%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 8 Analysts
Buy
50%
Hold
50%
Sell
0%
Markets Today
Today's Change
$-0.39 (-3.71%)
Day High
$10.70
Day Low
$10.01
Day Open
$10.35
Prev Close
$10.42
Volume
8,02,768
1W Return
11.23%
1M Return
8.56%
3M Return
27.57%
6M Return
73.88%
1Y Return
54.12%
Fundamentals
Market Cap ($ Mn)
550
PE Ratio
-
PB Ratio
5.46
PEG Ratio
-
ROE
-136.82%
ROCE
-69.23%
EPS (TTM)
$-0.60
Investment Returns
1 Week
11.23%
1 Month
8.56%
3 Months
27.57%
6 Months
73.88%
9 Months
30.30%
Financials
Quarterly
All values in $ Mn
6.3
Mar 25
6.6
Jun 25
8.1
Sep 25
14.3
Dec 25
14.5
Jun 26
19.6
Sep 26
Updates
10Nov
Mizuho maintains outperform on Senseonics, raises target to $20
Mizuho maintains Outperform rating on Senseonics Holdings. Price target raised from $18 to $20. Analyst Anthony Petrone issued the update.
2 days ago
10Nov
TD Cowen raises Senseonics Holdings price target to $17
TD Cowen maintains a Buy rating on Senseonics Holdings. Price target increased from $15 to $17. Analyst Joshua Jennings issued the update.
2 days ago
10Nov
Stifel raises Senseonics Holdings price target to $10, maintains hold
Stifel raised Senseonics Holdings' price target to $10 from $9. Stifel maintained its Hold rating on the stock. Barclays previously raised its target to $11 with an Equal-Weight rating.
2 days ago
10Nov
Senseonics Q3FY26 Results: Revenue up 140% to $19.6M, guidance raised
Revenue surged 141.64% YoY to $19.561 million, beating consensus estimates by 20.76%. Gross margin expanded to 62% from 43%, driven by bundled pay channel mix and in-house operations. Full-year revenue guidance raised to $68-70 million for the third time this fiscal year. Net loss per share narrowed to $(0.50) from $(0.43), beating analyst estimates. Beta Bionics partnership announced for iLet integration; Freedom CGM human testing began.
3 days ago
14Sep
Senseonics, Beta Bionics partner to integrate Eversense 365 with iLet system
Senseonics and Beta Bionics partner to integrate Eversense 365 CGM with iLet Bionic Pancreas. Integrated system enables automated insulin delivery without carb counting. Development completion expected in fourth quarter of 2026. Commercial launch planned post-integration, subject to regulatory requirements.
Senseonics Holdings reported Q2 2026 revenue of $14.5 million, a 120% YoY increase, with gross margins expanding to 59%. The company raised full-year revenue guidance to $62-$66 million, citing strong U.S. sales and Eversense 365 rollout, though net loss widened due to increased operating expenses from commercial integration.
